Goldman Sachs's Jami Rubin says AbbVie's pipeline assets make it a stealth competitor.
The commericalization/development deal covers up to six anti-cancer assets, and gives OncoMed a 50/50 US partnership over the experimental monoclonal antibody demcizumab.
Sanofi top-lined positive clinical data today from its investigational basal insulin, as it seeks to defend its position in this fast-growing segment.
Chronic disease patients seek online support and information, and show little love for branded websites.
Getting to an integrated mar-comms model isn't easy. Addressing your agency's lack of digital skills is a good start.
The drug failed to hit its Phase III targets.
Phase-IIIb study results indicate Lyxumia—which is approved abroad but not in the US—was "non-inferior" in terms of controlling blood sugar levels regardless of whether the shot was given before breakfast or later.
Novo's global diabetes study finds that only 29% of polled patients were asked what they thought about prescribed regimens.
Click on the image above to see a gallery of images from the 2013 MM&M Awards dinner
Missed MM&M's recent Skill Sets Live event on Multi-Screen Marketing? We're now giving you a second chance to get up to speed! Click here to access this insightful e-book with all the key take-aways.